Current Hepatitis Reports

, Volume 8, Issue 2, pp 73–80

STAT-C: New therapies cannot get here fast enough

Authors

    • Section of Hepatology and GastroenterologyShands Hospital, University of Florida
  • David R. Nelson
Article

DOI: 10.1007/s11901-009-0011-0

Cite this article as:
Morelli, G. & Nelson, D.R. Curr hepatitis rep (2009) 8: 73. doi:10.1007/s11901-009-0011-0
  • 21 Views

Abstract

The ability to culture hepatitis C virus (HCV) and the determination of the three-dimensional structure of the replication elements of the HCV genome allowed the rapid development of antiviral molecules directly targeting specific enzymes that allow HCV to reproduce itself. This new class of drugs, known as specifically targeted antiviral therapy for HCV (STAT-C), offers a new paradigm for the treatment of this elusive virus. During recent years, multiple STAT-C agents were introduced into clinical trials, but only a few have overcome the hurdles often associated with early clinical drug development. This article discusses the latest clinical trial findings on the emerging STAT-C agents for the treatment of HCV, particularly the agents that have progressed to phase 2 and phase 3 in clinical trials.

Download to read the full article text

Copyright information

© Current Medicine Group, LLC 2009